PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
G01N 33/48

A2

(11) International Publication Number: WO 99/50658

(43) International Publication Date: 7 October 1999 (07.10.99)

(21) International Application Number: PCT/US99/06937

(22) International Filing Date: 30 March 1999 (30.03.99)

(30) Priority Data:

60/079,956	30 March 1998 (30.03.98)	US
60/113,146	16 December 1998 (16.12.98)	US
60/113,014	16 December 1998 (16.12.98)	US

(71) Applicants *(for all designated States except US)*: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 12th floor, 1111 Franklin Street, Oakland, CA 94607–5200 (US). ARCH DEVELOPMENT CORPORATION [US/US]; 5640 South Ellis Avenue, Chicago, IL 60637 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: SHIAU, Andrew [US/US]; Apartment #13, 34 Hugo Street, San Francisco, CA 94122 (US). KUSHNER, Peter, J. [US/US]; 1362 6th Avenue, San Francisco, CA 94122 (US). AGARD, David, A. [US/US]; 238 Juanita Way, San Francisco, CA 94127 (US). GREENE, Geoffrey, L. [US/US]; Apartment 25F, 2020 Lincoln Park West, Chicago, IL 60614 (US).

(74) Agents: EBERLE, Shelley, P.; Cooley Godward LLP, Five Palo Alto Square, 3000 El Camino Real, Palo Alto, CA 94306–2155 (US) et al.

(81) Designated States: AU, CA, JP, KR, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: METHODS AND COMPOUNDS FOR MODULATING NUCLEAR RECEPTOR ACTIVITY

(57) Abstract

The present invention relates to methods and agonist/antagonist compounds for modulating nuclear receptor activity, and nuclear receptor ligand binding. The invention includes a method for identifying residues comprising a ligand binding domain for a nuclear receptor of interest. Also included in a method of identifying agonists and/or antagonists that bind to the ligand binding domain of the nuclear receptors, and the estrogen receptor in particular. The invention is exemplified by identification and manipulation of the ligand binding domain of the estrogen receptor and compounds that bind to this site. The methods can be applied to other nuclear receptors including TR, GR and PR.